Clinical and CT body-composition model for major pathological response to neoadjuvant tislelizumab, albumin-bound paclitaxel, and nedaplatin in esophageal squamous cell carcinoma
- 1Department of Radiology, The First Hospital of Putian City
- 2Department of Pathology, The First Hospital of Putian City
Abstract
Background: Sarcopenia and osteoporosis are linked to poor treatment outcomes and are significantly underdiagnosed in esophageal cancer patients. Despite the promising efficacy of neoadjuvant immunochemotherapy (NACI) in esophageal squamous cell carcinoma (ESCC), predicting treatment response remains a major clinical hurdle.
Objective: This study aimed to evaluate the associations of sarcopenia and osteoporosis on pathological response and to develop a both clinical and computed tomography (CT)-based predictive model for NACI outcomes in ESCC patients.
Methods: A retrospective analysis was conducted in 179 patients with ESCC who underwent radical resection after neoadjuvant tislelizumab, albumin-bound paclitaxel, and nedaplatin. Within each of 500 stratified bootstrap resamples, five-fold cross-validation was used to determine the optimal LASSO penalty parameter, followed by Firth logistic regression. Aggregated out-of-bag predictions underwent five-fold cross-fitted recalibration. Model discrimination, calibration, and clinical utility were evaluated using the AUC, accuracy, sensitivity, specificity, Brier score, calibration intercept and slope, Hosmer–Lemeshow test, and decision curve analysis.
Results: Major pathological response (MPR) rates were 70.0%, 40.0%, 22.0%, and 8.3% in the control, osteoporosis-only, sarcopenia-only, and osteosarcopenia groups, respectively. In multivariable Firth logistic regression, lower tumor grading, absence of comorbidities, absence of lymphovascular invasion, absence of sarcopenia, and a higher intermuscular adipose tissue (IMAT) area percentage were associated with a greater likelihood of achieving MPR, whereas osteoporosis was not associated with MPR (P = 0.130). The cross-fitted recalibrated model achieved an AUC of 0.885 (95% CI, 0.835–0.934), with 0.818 accuracy, 0.840 sensitivity, and 0.800 specificity at a threshold of 0.405. Calibration was satisfactory (Brier score, 0.136; intercept, −0.009; slope, 0.960; Hosmer–Lemeshow P = 0.219), and decision curve analysis showed clinical net benefit across thresholds of 0.08–0.80.
Conclusion: Absence of sarcopenia and a higher IMAT area percentage were associated with a greater likelihood of achieving major pathological response. The combined clinical and CT-based model showed good internally validated performance.
Related
- Pretreatment Body Composition Parameters and HALP Score in Relation to Pathological Complete Response in HER2-Positive Breast Cancer Receiving Neoadjuvant Systemic Therapy
- Pathological Complete Response and Successful Conversion Hepatectomy in Initially Unresectable Giant Hepatocellular Carcinoma Following Triple Therapy With HAIC, Bevacizumab, and Tislelizumab: A Case Report
- Relative change rate of neutrophil-to-albumin ratio (ΔNAR) during neoadjuvant chemotherapy predicts axillary pathological complete response in locally advanced breast cancer
- R0 resection following neoadjuvant PD-1 inhibition with paclitaxel-cisplatin is associated with improved overall survival in locally advanced and recurrent oral squamous cell carcinoma: multicenter retrospective cohort study.
- Advances in predictive factors for pathological complete response after neoadjuvant therapy in locally advanced rectal cancer
BibTeX
@article{xu2026clinical,
title = {{Clinical and CT body-composition model for major pathological response to neoadjuvant tislelizumab, albumin-bound paclitaxel, and nedaplatin in esophageal squamous cell carcinoma}},
author = {Huiran Xu and Wei Zheng and Shumei Chen and Suying Wu},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1859690},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1859690/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical and CT body-composition model for major pathological response to neoadjuvant tislelizumab, albumin-bound paclitaxel, and nedaplatin in esophageal squamous cell carcinoma
AU - Huiran Xu
AU - Wei Zheng
AU - Shumei Chen
AU - Suying Wu
PY - 2026
DA - 2026/10/30
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1859690
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1859690/full
AB - Background: Sarcopenia and osteoporosis are linked to poor treatment outcomes and are significantly underdiagnosed in esophageal cancer patients. Despite the promising efficacy of neoadjuvant immunochemotherapy (NACI) in esophageal squamous cell carcinoma (ESCC), predicting treatment response remains a major clinical hurdle. Objective: This study aimed to evaluate the associations of sarcopenia and osteoporosis on pathological response and to develop a both clinical and computed tomography (CT)-based predictive model for NACI outcomes in ESCC patients. Methods: A retrospective analysis was conducted in 179 patients with ESCC who underwent radical resection after neoadjuvant tislelizumab, albumin-bound paclitaxel, and nedaplatin. Within each of 500 stratified bootstrap resamples, five-fold cross-validation was used to determine the optimal LASSO penalty parameter, followed by Firth logistic regression. Aggregated out-of-bag predictions underwent five-fold cross-fitted recalibration. Model discrimination, calibration, and clinical utility were evaluated using the AUC, accuracy, sensitivity, specificity, Brier score, calibration intercept and slope, Hosmer–Lemeshow test, and decision curve analysis. Results: Major pathological response (MPR) rates were 70.0%, 40.0%, 22.0%, and 8.3% in the control, osteoporosis-only, sarcopenia-only, and osteosarcopenia groups, respectively. In multivariable Firth logistic regression, lower tumor grading, absence of comorbidities, absence of lymphovascular invasion, absence of sarcopenia, and a higher intermuscular adipose tissue (IMAT) area percentage were associated with a greater likelihood of achieving MPR, whereas osteoporosis was not associated with MPR (P = 0.130). The cross-fitted recalibrated model achieved an AUC of 0.885 (95% CI, 0.835–0.934), with 0.818 accuracy, 0.840 sensitivity, and 0.800 specificity at a threshold of 0.405. Calibration was satisfactory (Brier score, 0.136; intercept, −0.009; slope, 0.960; Hosmer–Lemeshow P = 0.219), and decision curve analysis showed clinical net benefit across thresholds of 0.08–0.80. Conclusion: Absence of sarcopenia and a higher IMAT area percentage were associated with a greater likelihood of achieving major pathological response. The combined clinical and CT-based model showed good internally validated performance.
SN - 2234-943X
ER -